Use of firsekibart for acute gouty arthritis in a maintenance hemodialysis patient with multiple high-risk comorbidities: a case report.
Objective To describe the clinical course of Firsekibart treatment for acute gouty arthritis in a 51-year-old patient receiving maintenance hemodialysis with multiple high-risk comorbidities, focusing on the temporal relationship among dialysis, drug administration and the timing of symptom changes. This report adds to the limited evidence on using Firsekibart, a novel fully human monoclonal antibody targeting IL-1β, in patients receiving maintenance hemodialysis. Methods We retrospectively r...